All In Biotech

Drug Trial Radar · NCT04109950

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

463

Actual

Start

Nov 20, 2019

Primary completion

Nov 9, 2023

Study completion Nov 9, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with schizophrenia. Participants in the study will receive the drug being studied. This study is accepting male and female participants between 13 and 65 years old who have been diagnosed with schizophrenia and have completed Study SEP361-301 (NCT04072354) or Study SEP361-302 (NCT04092686). This study will be conducted in approximately 80 study centers worldwide. The treatment duration for this study is one (1) year.

Conditions

  • Schizophrenia

Interventions

  • SEP-363856Drug

    SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of overall Adverse Events (AEs), Serious Adverse Events (AEs), and Adverse Events (AEs) leading to discontinuationTime frame: 53 Weeks

Locations

78 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Rogers, Arkansas

  • Research Site

    Anaheim, California

  • Research Site

    Culver City, California

  • Research Site

    Lemon Grove, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Montclair, California

  • Research Site

    San Diego, California

  • Research Site

    Sherman Oaks, California

  • Research Site

    Miami Springs, Florida

  • Research Site

    Oakland Park, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Lake Charles, Louisiana

  • Research Site

    Gaithersburg, Maryland

  • Research Site

    Flowood, Mississippi

  • Research Site

    St Louis, Missouri

  • Research Site

    Marlton, New Jersey

  • Research Site

    New York, New York

  • Research Site

    Dayton, Ohio

  • Research Site

    Austin, Texas

  • Research Site

    Richardson, Texas

  • Research Site

    Burgas, Bulgaria

  • Research Site

    Kardzhali, Bulgaria

  • Research Site

    Novi Iskar, Bulgaria

  • Research Site

    Pazardzhik, Bulgaria

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Veliko Tarnovo, Bulgaria

  • Research Site

    Vratsa, Bulgaria

  • Research Site

    Barranquilla, Colombia

  • Research Site

    Bogotá, Colombia

  • Research Site

    Zagreb, Croatia

  • Research Site

    Daugavpils, Latvia

  • Research Site

    Riga, Latvia

  • Research Site

    Strenči, Latvia

  • Research Site

    Chelyabinsk, Russia

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.